Schrödinger, Inc.

Schrödinger, Inc. develops a physics-based computational platform that enables the discovery of novel molecules for drug development and materials applications. The company operates in two primary segments: Software and Drug Discovery. The Software segment provides advanced computational tools to biopharmaceutical and biotechnology companies, as well as materials science firms, transforming molecular discovery processes in life sciences and related industries. The Drug Discovery segment builds a portfolio of preclinical and clinical programs, advancing proprietary candidates like the MALT1 inhibitor SGR-1505 and pursuing collaborations with partners such as Novartis, Lilly, Ajax Therapeutics, and Copernic Catalysts to target specific therapeutic areas including oncology and rare diseases. Founded in 1990 and headquartered in New York, Schrödinger, Inc. plays a pivotal role in accelerating innovation at the intersection of computational chemistry, AI-driven simulations, and drug design, supporting research from target identification through clinical validation.